Italia markets closed

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
9,42-0,77 (-7,56%)
Alla chiusura: 04:00PM EDT
9,43 +0,01 (+0,11%)
Dopo ore: 07:23PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente10,19
Aperto10,23
Denaro9,37 x 100
Domanda9,49 x 100
Min-Max giorno9,23 - 10,43
Intervallo di 52 settimane6,07 - 17,02
Volume951.785
Media Volume694.639
Capitalizzazione551,402M
Beta (mensile su 5 anni)0,67
Rapporto PE (ttm)N/D
EPS (ttm)-4,46
Prossima data utili08 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A22,88
  • GlobeNewswire

    Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

    Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studiesNew drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for vonoprazan as a daily treatment for Non-Erosive GERD, the largest subcategory of GERD with an estimated U.S. adult population of 38 millionFDA action date for Non-Erosive GERD ND

  • GlobeNewswire

    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

    FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference in New York City. Management will participate in one-on-one meetings on September 12, 2023.H.C. Wainwright 2

  • GlobeNewswire

    Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

    Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf lifeSubmission of six-month stability data satisfies Phathom's stability data submission requirements for Erosive GERD New Drug Application (NDA) for vonoprazan with a Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 FLORHAM PARK, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,